Latest Articles and Analysis

Research on elevated cancer risks in PLWHA and importance of early detection.

PLWHA face elevated cancer risks; screening, HPV vaccination, and coordinated care are critical.

OIG report: 27% of Medicaid HIV enrollees lack evidence of critical services; state disparities exposed.

Opioid settlement funds risk misallocation; MAT gaps for minors and drug court issues identified.

Australian study: 1% viral load suppression increase correlates with 6% decrease in HIV diagnoses.

Place-based sexual health care in community venues advances HIV/HCV prevention and testing outreach.

Provider language shows negative bias toward Black patients at 2.5x rate, undermining care engagement.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.